Literature DB >> 3917470

Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187.

M Oda, K Satouchi, K Yasunaga, K Saito.   

Abstract

Two species of platelet-activating factor (PAF), 1-hexadecyl- and 1-octadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16 = 0 AGEPC and C18 = 0 AGEPC) were detected in ionophore A23187-stimulated human neutrophils. The amount of AGEPC in 1 x 10(7) neutrophil cells was 80 +/- 26 pmol (mean +/- standard error) with a range of 14 to 223 pmol (n = 8), and it consisted of 80% of the C16 = 0 species and 20% of the C18 = 0 species. Most of the AGEPC derived from ionophore-treated neutrophils remained cell associated rather than being secreted into the medium, even when the medium contained ample albumin protein, which can trap AGEPC. These results were obtained by a technique of gas chromatography-mass spectrometry coupled with selected ion monitoring.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917470

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Mass spectrometric analysis of platelet-activating factor after isolation by solid-phase extraction and direct derivatization with pentafluorobenzoic anhydride.

Authors:  S T Weintraub; R K Satsangi; E A Sprague; T J Prihoda; R N Pinckard
Journal:  J Am Soc Mass Spectrom       Date:  2000-02       Impact factor: 3.109

2.  Radioimmunoassay for platelet-activating factor.

Authors:  K Karasawa; N Satoh; T Hongo; Y Nakagawa; M Setaka; S Nojima
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Determination of platelet-activating factor by a chemiluminescence method and its application to stimulated guinea pig neutrophils.

Authors:  Y Hasegawa; E Kunow; J Shindou; H Yuki
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

4.  Effect of Staphylococcus aureus delta-toxin on human granulocyte functions and platelet-activating-factor metabolism.

Authors:  S Kasimir; W Schönfeld; J E Alouf; W König
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

Review 5.  Structural and (patho)physiological diversity of PAF.

Authors:  R N Pinckard; D S Woodard; H J Showell; M J Conklyn; M J Novak; L M McManus
Journal:  Clin Rev Allergy       Date:  1994

6.  1-Acyl-2-acetyl-sn-glycero-3-phosphocholine from stimulated human polymorphonuclear leukocytes.

Authors:  K Satouchi; M Oda; K Saito
Journal:  Lipids       Date:  1987-04       Impact factor: 1.880

7.  Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers.

Authors:  Y Hirashima; S Endo; N Hayashi; K Karasawa; S Nojima; A Takaku
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

8.  Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.

Authors:  A J Wardlaw; R Moqbel; O Cromwell; A B Kay
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

9.  Platelet activating factor, lyso-platelet activating factor and arachidonic acid release in normal human skin and the influence of topical steroid treatment.

Authors:  R M Barr; F Lawlor; M R Judge; P Courtney; R Barlow; A Kobza Black; A I Mallet; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

10.  Immunofluorescent localization of platelet-activating factor (PAF) in the rat.

Authors:  Y Hirashima; R Kato; S Endo; A Takaku; K Karasawa; S Nojima
Journal:  Histochem J       Date:  1993-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.